紫杉醇化疗应用小剂量地塞米松预处理的临床观察

目的 观察含紫杉醇方案化疗时应用小剂量地塞米松预处理的效果及安全性，探索紫杉醇化疗预处理的新方案。方法 151例患者应用紫杉醇联合铂类方案，紫杉醇135～175mg／m2，21天为1周期。依据输注紫杉醇前采用的两种不同地塞米松预处理方案，将151例患者分为标准组（n=75）和小剂量组（n=76），比较两组的不良反应。结果 小剂量组与标准组的急性过敏发生率分别为8.0％、9.2％；外周神经毒性中周围神经炎发生率分别为38.7％、40.8％；肌肉关节痛发生率分别为52.0％、53.9％，两组不良反应差异均无统计学意义。结论 紫杉醇化疗前应用小剂量地塞米松预处理与标准预处理方案合并急性过敏反应的发生率并无差异。

Clinical observation of paclitaxel chemotherapy by low-dose dexamethasone premedication

Objective To observe the safety and adverse reactions of the low-dose dexamethasone premedication with paclita-xel chemotherapy, explore a new paclitaxel premedication procedure. Methods Paclitaxel（135-175mg/m2） combined with platinum drugs was used in 151 patients, 21 days was a cycle. Two kinds of the premedication procedure be used before injection of paclitaxel, one in standard premedication procedure, the other in low-dose dexamethasone premedication procedure, observe the drug safety and adverse reactions. Results Paclitaxel chemotherapy in 75 cases of low-dose dexamethasone premedication and 76 cases of standards with acute allergy rates were 8.0% and 9.2%; peripheral neuritis rate were 38.7% and 40.8%, muscle and joint pain rate were 52.0%, 53.9%. There was no statistically significant between the two groups. Conclusion There was no difference in acute allergic reaction of paclitaxel chemotherapy before the application of Low-dose dexamethasone premedication compared with standards.